Atwood & Palmer Inc. continued to hold its stake in Opko Health, Inc. (NASDAQ:OPK) during the second quarter, according to its most recent disclosure with the SEC. The firm owned 100,000 shares of the biotechnology company’s stock at the end of the second quarter. Atwood & Palmer Inc.’s holdings in Opko Health were worth $658,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. BlackRock Inc. raised its stake in Opko Health by 11,481.3% in the first quarter. BlackRock Inc. now owns 22,645,285 shares of the biotechnology company’s stock worth $181,163,000 after buying an additional 22,449,752 shares during the last quarter. State Street Corp raised its stake in Opko Health by 40.3% in the first quarter. State Street Corp now owns 10,926,560 shares of the biotechnology company’s stock worth $87,412,000 after buying an additional 3,138,685 shares during the last quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management raised its stake in Opko Health by 62.4% in the first quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management now owns 5,061,154 shares of the biotechnology company’s stock worth $40,489,000 after buying an additional 1,944,549 shares during the last quarter. Vanguard Group Inc. raised its stake in Opko Health by 4.4% in the first quarter. Vanguard Group Inc. now owns 26,322,001 shares of the biotechnology company’s stock worth $210,576,000 after buying an additional 1,112,843 shares during the last quarter. Finally, Skandinaviska Enskilda Banken AB publ acquired a new stake in Opko Health during the first quarter worth about $4,450,000. 22.46% of the stock is owned by institutional investors and hedge funds.

Shares of Opko Health, Inc. (NASDAQ OPK) traded up 0.080% during midday trading on Wednesday, hitting $6.235. 658,564 shares of the company were exchanged. Opko Health, Inc. has a 52-week low of $5.85 and a 52-week high of $12.15. The stock’s market capitalization is $3.49 billion. The company has a 50-day moving average price of $6.24 and a 200-day moving average price of $7.11.

Opko Health (NASDAQ:OPK) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. The firm had revenue of $314.20 million during the quarter, compared to the consensus estimate of $322.64 million. Opko Health had a negative return on equity of 3.67% and a negative net margin of 6.52%. The business’s revenue for the quarter was down 12.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.02 EPS. On average, analysts forecast that Opko Health, Inc. will post ($0.20) EPS for the current year.

WARNING: “Atwood & Palmer Inc. Has $658,000 Position in Opko Health, Inc. (OPK)” was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/atwood-palmer-inc-has-658000-position-in-opko-health-inc-opk/1532090.html.

A number of equities research analysts recently issued reports on OPK shares. Zacks Investment Research lowered shares of Opko Health from a “hold” rating to a “sell” rating in a report on Thursday, May 4th. Cantor Fitzgerald started coverage on shares of Opko Health in a report on Thursday, August 17th. They issued an “overweight” rating and a $20.00 price objective for the company. Ladenburg Thalmann Financial Services reissued a “buy” rating and issued a $19.50 price objective on shares of Opko Health in a report on Friday, June 16th. BidaskClub raised shares of Opko Health from a “sell” rating to a “hold” rating in a report on Monday, July 24th. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $8.00 price objective on shares of Opko Health in a report on Monday, June 12th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the stock. Opko Health has a consensus rating of “Buy” and an average price target of $15.28.

In other news, CEO Phillip Md Et Al Frost purchased 55,000 shares of the business’s stock in a transaction dated Monday, June 5th. The stock was bought at an average cost of $6.31 per share, with a total value of $347,050.00. Following the purchase, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at $19,365,080.81. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director John A. Paganelli purchased 5,000 shares of the business’s stock in a transaction dated Thursday, June 1st. The shares were purchased at an average cost of $6.17 per share, with a total value of $30,850.00. Following the completion of the purchase, the director now directly owns 350,340 shares in the company, valued at $2,161,597.80. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 1,230,900 shares of company stock valued at $7,810,266. Company insiders own 40.19% of the company’s stock.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Want to see what other hedge funds are holding OPK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Opko Health, Inc. (NASDAQ:OPK).

Institutional Ownership by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.